Introduction {#S1}
============

Autoimmune diseases (ADs) are a complex class of diseases resulting from the immune system failure to differentiate between self and foreign antigens ([@B1]). This misrecognition directs the immune system to attack self-antigens, which consequently modifies the biological functions of the affected tissues. Ultimately, tissue damage and dysfunctions ensue and present as clinical symptoms. However, the onset of clinical symptoms is often delayed and occurs following irreversible damage to the affected tissues or organ. There is a global urgency for the discovery of specific and sensitive biomarkers for an early detection of ADs. Additionally, the ideal AD biomarker(s) should also be surrogate for disease severity, progression to disability and response to therapy ([@B2]).

The discovery of such biomarkers is not straightforward. Currently, validated biomarkers do not yet fulfill this tall order (we list validated biomarkers from select ADs in Table S1 in Supplementary Material). The immune system biology is dynamic---it varies with genetic background, age, sex, and the environment ([@B3]--[@B11]). Thus, patients with varying characteristics may present with different clinical phenotype and biomarkers despite suffering from the same AD. Conventional biomarker research strategy has been reductionist and aggregated: they compare all AD patients and controls of mixed baseline characteristics. This approach, although suboptimal, has been productive, leading to the discovery of many novel AD biomarkers ([@B2]). Yet, validation and clinical translation of such novel biomarkers have proven to be challenging, possibly due to: (1) lack of control and patient group stratification and matching; (2) inappropriate biomarker validation strategy; and/or (3) techniques used in clinical trials ([@B12], [@B13]). In this review, we highlight the importance of sex stratification in AD biomarker research prior to the discovery-phase, by drawing attention to the fact that: (1) ADs display stronger female bias and (2) present with different disease trajectories in males and females. There are apparent sex differences in AD pathophysiology. These need to be recognized and hopefully over time, incorporated into AD research efforts, clinical diagnosis, and management for a better patient outcome.

Methods {#S2}
=======

We assembled a comprehensive list of disease prevalence and associated biomarkers in females and males from different geographical locations. Extensive literature review for the study variables of interest for each of the diseases was mainly carried out using PubMed, although some books and online resources were also consulted. Standard search strategies were used, including medical subject headings such as "disease name" and "biomarker," or "disease name" and other parameters of interest (e.g., "prevalence," "in Japan," "diagnosis," "autoantibodies," etc.). Of note, we searched in futility for "sex/gender differences," "disease name," and "biomarkers," perhaps highlighting the paucity of such studies. In total, we reviewed \>1,000 abstracts and \>400 full papers and included papers which fulfilled the following criteria: Table [1](#T1){ref-type="table"}, review papers and an immunology textbook describing sex-biased immune responses in humans, i.e., Ref. ([@B3], [@B4], [@B14]).Table [2](#T2){ref-type="table"}, clinical studies indicating numbers of females and males in their study. Studies in which the male and female numbers were not representative of the disease prevalence and incidence in that particular geography were excluded.Tables [3](#T3){ref-type="table"}--[6](#T6){ref-type="table"}, only reviews \[i.e., Ref. ([@B15]--[@B19])\] or primary clinical research papers reporting at least one significant (*P* \< 0.05) sex-bias in clinical phenotype was reported.Table S1 in Supplementary Material, review papers and primary research papers that propose novel serum- or plasma-derived proteomic biomarkers. Only biomarkers that have been validated in multiple clinical studies are included. Often this means seeing multiple papers reporting the same biomarkers. Exclusion criteria include:generic biomarkers such as metabolites and oxidative stress biomarkers, likely to be observed with other diseases;genetic biomarkers such as DNA, RNA, single nucleotide polymorphisms, etc.;biomarkers derived from site-specific fluids, such as synovial and cerebrospinal fluids, urine, tears, fecal matter, etc.

###### 

Sex dimorphism of the immune system biology.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Immune component                   Cytokines ([@B14])                                                                                        Sex differences (females vs males) ([@B3])     Effects of sex hormones ([@B3], [@B4], [@B24])                                                                       
  ---------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------ -------------------------------------------
  **Innate immunity**                                                                                                                                                                                                                                                                                              

  Toll-like receptor (TLR) pathway   Inflammatory cytokines, chemotactic factors, antimicrobial peptides, type I interferons (IFNα and IFNβ)   ↑ TLR gene expression\                         ↑ TLR4, TLR7, TLR9                                                  ↓ TLR3, TLR7                                     ↓ TLR4
                                                                                                                                               ↑ TLR7 expression\                                                                                                                                                  
                                                                                                                                               ↓ IL-10 production by TLR-9 stimulated PBMCs                                                                                                                        

                                                                                                                                                                                                                                                                                                                   

  Antigen-presenting cells (APCs)    Interleukins: IL 12, IL 17 ([@B20])                                                                       ↑ APC efficiency                               ↓ Antigen presentation ([@B21])                                     ↑ Antigen presentation ([@B22])                  ↓ Antigen presentation ([@B23])

                                                                                                                                                                                                                                                                                                                   

  Dendritic cells (DCs)              Interferons: IFNα\                                                                                        ↑ TLR7 activity\                               ↑ Activation, TLR7, TLR9,\                                          ↑ IL10, IL18, CD11c\                             Not defined
                                     Interleukins: IL10, IL12, IL23, IL27, IL28, IL29, IL37                                                    ↑ Type I interferon (IFN) activity             ↑ Production of CCL2, IL6, IL8 and IL12\                            ↓ CD40, CD80, CD86                               
                                                                                                                                                                                              ↑ Expansion of IFNγ-producing killer DCs from mature splenic DCs\                                                    
                                                                                                                                                                                              ↓ CXCL10, IFNα                                                                                                       

                                                                                                                                                                                                                                                                                                                   

  Macrophage                         Colony stimulating factors: GM-CSF\                                                                       ↑ Activation levels\                           ↑ TLR4\                                                             ↑ FIZZ1, YM1\                                    ↓ TNF and iNOS/NO
                                     Interferons: IFNα,\                                                                                       ↑ Phagocytic capacity\                         ↓ IL1β, IL6 and TNF production                                      ↓ iNOS, NO                                       
                                     Interleukins: IL1α, IL1β, IL6, IL10, IL12, IL15, IL18, IL23, IL27, oncostatin\                            ↑ IL-10 production\                                                                                                                                                 
                                     TNF family: TNFα                                                                                          ↓ Pro-inflammatory cytokine production\                                                                                                                             
                                                                                                                                               ↓ TLR4 expression                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                   

  Eosinophil                         IFNα, IL16                                                                                                                                               ↓ Count and mobilization                                            ↑ Count                                          Not defined

                                                                                                                                                                                                                                                                                                                   

  Neutrophil                         IFNγ, IL17                                                                                                ↑ Phagocytic capacity\                         ↑ Count, anti-inflammatory activity, elastase release\              Not defined                                      ↑ Count\
                                                                                                                                               ↓ TLR expression levels                        ↓ Chemotactic activity                                                                                               ↓ Kinases and Leukotriene formation

                                                                                                                                                                                                                                                                                                                   

  NK Cells                           Interferons: IFNγ\                                                                                        ↓ Cell count                                   ↑ IFNγ, Granzyme B\                                                 ↑ Cell count and apoptosis (caspase dependent)   Not defined
                                     Interleukins: IL17, IL26, IL32\                                                                                                                          ↓ FASL\                                                                                                              
                                     TNF family: TNFα                                                                                                                                         ↓ Cytotoxic activity                                                                                                 

  **Adaptive immunity**                                                                                                                                                                                                                                                                                            

  T-cells                            Colony stimulating factors: GM-CSF, M-CSF\                                                                ↑ CD4+ T cell count ([@B25])\                  Low estradiol: ↑ IFNγ and T~H~1 cells responses\                    ↓ T~H~1 cells activity\                          ↓ IFNγ production by T~H~1 cells\
                                     Interferons: IFNγ\                                                                                        ↑ CD4/CD8 T cell ratio\                        High estradiol: ↑ IL4 and T~H~2 cells responses\                    ↑ T~H~2 cells activity\                          ↓ T~H~2 expression of IL4, IL5 and GATA3\
                                     TNF family: TNFα, lymphotoxin, CD40L, FasL, CD27L, CD30L, APRIL, LIGHT, BAFF\                             ↑ Activated T cells count\                     ↑ T~reg~ cell count\                                                ↓ % of T~H~17\                                   ↑ IL17\
                                     Interleukins: IL2, IL4, IL5, IL6, IL9, IL10, IL13, IL16, IL24, IL32, oncostatin\                          ↑ T cell proliferation\                        ↑ Response of CD8+ T cells\                                         ↓ % of T~reg~\                                   ↑ T~reg~ cell count\
                                     T~H~1 cells: IL20\                                                                                        ↓ CD8+ count\                                  ↑ secretion of IFNγ and IL10 ([@B24])\                              ↓ Response of CD8+ T cells                       ↓ CD8+ cell count and activity
                                     T~H~2 cells: IL21, IL25, IL31\                                                                            ↑ CD8+ cytotoxicity\                           ↑ CD4+ CCR1 and CCR5 expression\                                                                                     
                                     T~H~17 cells: IL17, IL26\                                                                                 ↑ T~H~2 bias\                                  ↓ T~H~17 cell count and IL17 expression\                                                                             
                                     T~reg~: IL35                                                                                              ↓ T~H~1 bias\                                  ↓ CD4+ TNF production                                                                                                
                                                                                                                                               ↓ T~reg~ cell count\                                                                                                                                                
                                                                                                                                               ↑ T~H~1 cytokine secretion                                                                                                                                          

                                                                                                                                                                                                                                                                                                                   

  B-cells                            Lymphotoxin                                                                                               ↑ B-cell count\                                ↑ IgM and IgG prodction\                                            ↑ Total antibody production\                     ↓ Response
                                                                                                                                               ↑ Antibody production                          ↑ Survival of autoreactive B cells\                                 ↓ Autoantibodies                                 
                                                                                                                                                                                              ↓ Negative selection of naïve B cells                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Female-to-male ratio of autoimmune diseases (ADs) from different regions of the world.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Class                                                           Female: Male ratio                                                                                                                                          
  --------------------------------------------------------------- -------------------------------------- --------------------------------------- ------------------------------------- -------------------------------------- ----------------------------------------
  **Systemic and connective tissue**                                                                                                                                                                                          

  Systemic lupus erythematosus                                    6 ([@B26])--11.6 ([@B27]):1            4.7:1 ([@B28]) (Sweden)                 5.8:1 ([@B29]) (France)               4.4:1 ([@B30])                         7.8 ([@B31])--11.4 ([@B32]):1 (China)\
                                                                                                                                                                                                                              6:1 ([@B33]) (Korea)\
                                                                                                                                                                                                                              8.2:1 ([@B34]) (Japan)

                                                                                                                                                                                                                              

  Sjögren's syndrome                                              5.5:1 ([@B35])                         8 ([@B28])--8.7 ([@B36]):1 (Sweden)     15.8:1 ([@B37])\                      8.3:1 ([@B39])                         4.2:1 ([@B40]) (India)\
                                                                                                                                                 18.6:1 ([@B38]) (Spain)                                                      17.4:1 ([@B41]) (Japan)\
                                                                                                                                                                                                                              17:1 ([@B42]) (China)

                                                                                                                                                                                                                              

  **Pulmonary**                                                                                                                                                                                                               

  Idiopathic pulmonary fibrosis                                   0.9 ([@B43])--1.2 ([@B44]):1           0.3:1 ([@B45]) (Denmark)\               0.7:1 ([@B47]) (Spain)\               0.5:1 ([@B50])                         0.3:1 ([@B51]) (Korea)\
                                                                                                         0.4:1 ([@B46]) (Sweden)                 0.6:1 ([@B48]) (UK)\                                                         0.4:1 ([@B52]) (Japan)
                                                                                                                                                 0.3:1 ([@B49]) (Germany)                                                     

                                                                                                                                                                                                                              

  **Skin**                                                                                                                                                                                                                    

  Scleroderma (also systemic)                                     4.8:1 ([@B53])                         3.2:1 ([@B28]) (Denmark)\               9.7:1 ([@B55]) (Italy)\               7.4:1 ([@B59])                         7.7:1 ([@B34]) (Japan)\
                                                                                                         3.8:1 ([@B54]) (Norway)                 4.7 ([@B56])--7.2:1 ([@B57]) (UK)\                                           4 ([@B60]) -- 10 ([@B61]):1 (India)
                                                                                                                                                 10.4:1 ([@B58]) (France)                                                     

                                                                                                                                                                                                                              

  Psoriasis                                                       1 ([@B62])--1.3 ([@B63]):1             1.1:1 ([@B28]) (Denmark)\               1.3:1 ([@B65]) (Spain)\               2:1 ([@B68])                           0.6:1 ([@B69]) (Japan)
                                                                                                         1:1 ([@B64]) (Norway)                   0.8:1 ([@B66]) (Germany)\                                                    
                                                                                                                                                 1:1 ([@B67]) (UK)                                                            

                                                                                                                                                                                                                              

  **Hematopoetic and vascular**                                                                                                                                                                                               

  Antiphospholipid syndrome                                       3.6:1 ([@B70], [@B71])                 4.5:1 ([@B72]) (Norway)                 2.1:1 ([@B73]) (Spain)\                                                      5.4:1 ([@B76]) (Japan)\
                                                                                                                                                 1.7:1 ([@B74]) (Italy)\                                                      4.4:1 ([@B77]) (Singapore)
                                                                                                                                                 10:1 ([@B75]) (UK)                                                           

                                                                                                                                                                                                                              

  Immune thrombocytopenic purpura                                 1.1 ([@B78])--1.4 ([@B79], [@B80]):1   1.7:1 ([@B81]) (Denmark)                1.7:1 ([@B82]) (France)\              1.3 ([@B85])--1.6 ([@B86], [@B87]):1   1.6 ([@B88])--2.2 ([@B89]):1 (China)\
                                                                                                                                                 1.4:1 ([@B83]) (Germany)\                                                    1.9:1 ([@B90]) (India)\
                                                                                                                                                 1.3:1 ([@B84]) (UK)                                                          4.3:1 ([@B91]) (Singapore)

                                                                                                                                                                                                                              

  **Endocrine**                                                                                                                                                                                                               

  Grave's disease                                                 6:1 ([@B92])                           5.8:1 ([@B93]) (Denmark)                3.5:1 ([@B94]) (Greece)\              4:1 ([@B96])                           2.5--2.8:1 ([@B97]) (China)
                                                                                                                                                 4.4:1 ([@B95]) (France)                                                      

                                                                                                                                                                                                                              

  Hashimoto's thyroiditis                                         11.8:1 ([@B98])                        4.4:1 ([@B28])                          5.4:1 ([@B94]) (Greece)               7.3:1 ([@B99])                         10.7:1 ([@B100]) (China)\
                                                                                                                                                                                                                              21.7:1 ([@B101]) (India)

                                                                                                                                                                                                                              

  Type 1 diabetes (adult\*)                                       1:1 ([@B102])                          0.8:1 ([@B103])                         0.5:1 ([@B104]) (Italy)\              0.9--1.5:1 ([@B105], [@B106])          1.3:1 ([@B107]) (India)\
                                                                                                                                                 0.6:1 ([@B104]) (Spain)\                                                     1.4:1 ([@B108]) (Japan)
                                                                                                                                                 0.5--0.8:1 ([@B104], [@B105]) (UK)\                                          
                                                                                                                                                 1:1 ([@B105]) (Germany)                                                      

                                                                                                                                                                                                                              

  **Gastrointestinal and liver**                                                                                                                                                                                              

  Primary biliary cholangitis                                     10 ([@B109])--12.4 ([@B110]):1         4.1:1 ([@B28])                          7.9:1 ([@B111]) (France)\             9:1 ([@B113])                          10.5:1 ([@B114]) (China)\
                                                                                                                                                 12.6:1 ([@B112]) (UK)                                                        6.5:1 ([@B115]) (Japan)

                                                                                                                                                                                                                              

  Autoimmune hepatitis                                            4.1:1 ([@B116])                        3.17:1 ([@B117]) (Sweden)\              5.5:1 ([@B120]) (Spain)\              2.7:1 ([@B123]) (NZ)\                  6.7:1 ([@B125]) (Japan)\
                                                                                                         4:1 ([@B118]) (Norway)\                 7.1:1 ([@B121]) (Italy)\              3:1 ([@B124]) (AUS)                    5.9:1 ([@B126]) (China)\
                                                                                                         2.6:1 ([@B119]) (Denmark)               2.7:1 ([@B122]) (Germany)                                                    8.4:1 ([@B127]) (India)\
                                                                                                                                                                                                                              11:1 ([@B128]) (Singapore)

                                                                                                                                                                                                                              

  Ulcerative colitis                                              0.9:1 ([@B129])                        1:1 ([@B72])                            0.9:1 ([@B70]) (France)\              1.1:1 ([@B71])                         1.05:1 ([@B76]) (India)\
                                                                                                                                                 0.8:1 ([@B71]) (Western EU)                                                  0.7:1 ([@B77]) (Asia)\
                                                                                                                                                                                                                              0.9:1 ([@B73]) (Japan)

                                                                                                                                                                                                                              

  Crohn's disease                                                 1:1 ([@B129])                          1.1:1 ([@B28])                          1.32:1 ([@B70]) (France)\             1:1 ([@B71])                           1:1 ([@B76]) (India)\
                                                                                                                                                 0.7:1 ([@B71]) (Western EU)                                                  0.6:1 ([@B77]) (Asia)\
                                                                                                                                                                                                                              0.4:1 ([@B73]) (Japan)

                                                                                                                                                                                                                              

  Celiac disease (adult[^a^](#tfn1){ref-type="table-fn"}) (CoD)   1.3 ([@B74])--2.7 ([@B75]):1           1.8:1 ([@B28]) (Denmark)\               1:1 ([@B130]) (Germany)\              1.6:1 ([@B132])                        0.7:1 ([@B133]) (India)\
                                                                                                         1.2:1 ([@B130]) (Finland)\              0.6:1 ([@B130]) (Italy)\                                                     1.3:1 ([@B134]) (China)
                                                                                                         2.4:1 ([@B131]) (Sweden)                0.5:1 ([@B130]) (UK)                                                         

                                                                                                                                                                                                                              

  **Musculoskeletal**                                                                                                                                                                                                         

  Ankylosing spondylitis                                          0.3:1 ([@B135])                        0.5:1 ([@B28]) (Denmark)\               0.2:1 ([@B138]) (Greece)              0.4:1 ([@B139])                        0.3:1 ([@B140]) (China)\
                                                                                                         0.4:1 ([@B136]) (Finland)\                                                                                           0.2:1 ([@B141]) (India)\
                                                                                                         0.5:1 ([@B137]) (Sweden)                                                                                             0.2--0.3:1 ([@B142]) (Japan)

                                                                                                                                                                                                                              

  Rheumatoid arthritis                                            2.6:1 ([@B143])                        2.2:1 ([@B28]) (Denmark)                2.2:1 ([@B144]) (UK)                                                         3.8:1 ([@B140]) (China)

                                                                                                                                                                                                                              

  Psoriatic arthritis                                             0.7:1 ([@B145])                        1.23:1 ([@B137]) (Sweden)\              0.2:1 ([@B138]) (Greece)                                                     
                                                                                                         0.6:1 ([@B146]) (Norway)                                                                                             

                                                                                                                                                                                                                              

  **Neurological**                                                                                                                                                                                                            

  Multiple sclerosis                                              2.6:1 ([@B147])                        2 ([@B148])--2.3 ([@B28]):1 (Denmark)   2.4:1 ([@B149]) (France)              2.3 ([@B150])--4.5 ([@B151]):1         1.8:1 ([@B152]) (China)\
                                                                                                                                                                                                                              2.9:1 ([@B153]) (Japan)\
                                                                                                                                                                                                                              1.7:1 ([@B154]) (India)

                                                                                                                                                                                                                              

  Myasthenia gravis                                               1.4:1 ([@B155])                        1.1:1 ([@B28])                          1.9:1 ([@B156]) (Italy)\              1.3:1 ([@B158])                        2:1 ([@B159]) (Japan)\
                                                                                                                                                 1.4:1 ([@B157]) (France)                                                     0.4:1 ([@B160]) (India)\
                                                                                                                                                                                                                              1.15:1 ([@B161]) (China)

                                                                                                                                                                                                                              

  Guillain--Barré syndrome                                        0.8:1 ([@B162])                        0.6:1 ([@B163]) (Finland)\              0.6:1 ([@B165]) (Italy)\              0.6:1 ([@B168])                        0.7:1 ([@B169]) (India)\
                                                                                                         0.8:1 ([@B164]) (Sweden)                0.6 ([@B166])--0.8 ([@B167]):1 (UK)                                          0.7:1 ([@B170]) (China)\
                                                                                                                                                                                                                              0.6:1 ([@B171]) (Japan)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Data reflect non-pregnant females*.

*^a^Adult: 15 ≤ Age ≤ 65*.

###### 

Sex differences in systemic lupus erythematosus clinical phenotypes.

  Clinical phenotype                                             Studies showing phenotype is increased in males                                                                Studies showing phenotype is increased in females                                                                                                                         Studies showing statistically in insignificant in males and females
  -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  Mortality                                                      ([@B27], [@B172])                                                                                                                                                                                                                                                                        
  Disease activity                                               ([@B17], [@B27], [@B173])                                                                                                                                                                                                                                                                ([@B174])
  Alopecia                                                                                                                                                                      ([@B18], [@B27], [@B32], [@B175]--[@B182])                                                                                                                                ([@B183])
  Photosensitivity                                                                                                                                                              ([@B18], [@B27], [@B176], [@B178], [@B179], [@B184], [@B185])                                                                                                             ([@B181], [@B183])
  Discoid lesions                                                ([@B32], [@B181], [@B186]--[@B188])                                                                                                                                                                                                                                                      ([@B183])
  Malar rash                                                                                                                                                                    ([@B18], [@B27], [@B181], [@B186], [@B189])                                                                                                                               ([@B183])
  Raynaud's phenomenon (RP)                                                                                                                                                     ([@B17], [@B27], [@B32], [@B176]--[@B179], [@B184], [@B185], [@B190], [@B191])                                                                                            
  Musculoskeletal (myositis, tendonitis, arthralgia/arthritis)   ([@B178])                                                                                                      ([@B17], [@B18], [@B27], [@B173], [@B176], [@B177], [@B179], [@B185], [@B186], [@B188], [@B192], [@B193])                                                                 ([@B16], [@B174], [@B181], [@B183])
  Oral ulcers                                                                                                                                                                   ([@B18], [@B27], [@B181], [@B184], [@B194])                                                                                                                               ([@B183])
  Serositis                                                      ([@B17], [@B18], [@B175], [@B178], [@B181], [@B182], [@B184], [@B187])                                                                                                                                                                                                                   ([@B174], [@B183], [@B186])
  Gastrointestinal complications                                 ([@B179])                                                                                                                                                                                                                                                                                
  Renal disease                                                  ([@B17], [@B18], [@B27], [@B174], [@B176], [@B177], [@B185], [@B187]--[@B191], [@B195], [@B196])                                                                                                                                                                                         ([@B16], [@B181], [@B183], [@B186])
  Neurological and psychiatric disease                           ([@B182], [@B185]), Seizure ([@B197]), peripheral neuropathy ([@B17])                                          Psychosis ([@B177]), psychiatric ([@B17], [@B175])                                                                                                                        ([@B181], [@B183], [@B186])
  Hematological: thrombocytopenia, leukopenia                    ([@B18], [@B27], [@B177], [@B195])                                                                             ([@B17], [@B174], [@B175], [@B182], [@B184], [@B188], [@B191])                                                                                                            ([@B181], [@B183], [@B186])
  Cardiovascular                                                 ([@B27], [@B176], [@B179], [@B187])                                                                                                                                                                                                                                                      ([@B181])
  Thromboses                                                     ([@B27], [@B179], [@B180], [@B190], [@B193])                                                                                                                                                                                                                                             
  Other                                                          Constitutional symptoms: fever, weight loss ([@B176]), pleuritis ([@B181]), dry mouth and dry eyes ([@B185])   Flares/severe flares ([@B32]); cutaneous ([@B174]); more frequent relapses ([@B17]), erythrocyte sedimentation rate, antinuclear antibody, anti-SSA, anti-SSB ([@B181])   Mucocutaneous ([@B16], [@B193]), vasculitis ([@B181], [@B186]), low C3, anti-dsDNA, anti-Sm, anti-rRNP ([@B181], [@B193])

*Adapted with modifications from Ref. ([@B15]--[@B18])*.

*The results depict studies where significant (*P* \< 0.05) differences were detected*.

###### 

Comparative studies of male and female lupus: main clinical and demographic findings, adapted with modifications from Ref. ([@B1], [@B8], [@B15]--[@B17]).

  ------------------------------------------- ---------------------------------- ----------------------------- ------------------ -------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------------------------------
  **Year of Study**                           **Country (ethnicity)**            **Study type**                **Size (%male)**   **Age at onset**     **Clinical phenotype (***P*** \< 0.05)**                                          **Serology**                                                                   

                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                       **Increased in males**                                                             **Increased in females**                                                      

  **North America**                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                        

  NA                                          US (multiethnic) ([@B173])         Prospective                   618 (10.2)         37.1 (M), 36.5 (F)   Renal disease                                                                     Musculoskeletal                                                                LAC (M)

  1969--1983                                  US ([@B198])                       Inception                     361 (17.2)         44.7 (M), 35.2 (F)   Seizures                                                                                                                                                         

  1982--1983                                  US ([@B175])                       Prospective control           100 (50)           45 (M), 44 (F)       Serositis                                                                         Neurological, alopecia, ↓ platelets                                            

  1987--2012                                  US (multiethnic) ([@B27])          Retrospective                 1979 (7.9)         49.8 (M), 37.6 (F)   Hypertension, renal disease,\                                                     Malar rash, RP, photosensitivity, oral ulcers, alopecia, arthralgia            Anti-Sm, DAT, LAC, anti-dsDNA, low C3 (M)
                                                                                                                                                       Thrombotic episode, hypertension, disability, lymphopenia                                                                                                        

  2002--2007                                  US (multiethnic) ([@B195])         Case--control                 265 (9)            NA                   Proteinuria, lymphopenia, platelets count                                                                                                                        6 antibodies assayed, *P* \> 0.05

                                                                                                                                                                                                                                                                                                                        

  **Latin America**                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                        

  1997--2005                                  Latin America ([@B176])            Inception                     1213 (10.1)        27 (M), 29.2 (F)     Constitutional symptoms, hypertension, proteinuria, any renal, hemolytic anemia   Arthralgia, alopecia, RP, photosensitivity, any cutaneous                      Low C3,\
                                                                                                                                                                                                                                                                                                                        IgG aCL (M)

  1972--1993                                  Latin America ([@B190])            Cross-sectional               1316 (8.1)         26 (M), 28 (F)       Renal disease                                                                     RP                                                                             dsDNA (M)

  2000--2011                                  Colombia (multiethnic) ([@B16])    Cross-sectional               160 (25)           32.0 (M), 30.5 (F)   Severe disease activity                                                           Alopecia                                                                       anti-SSA/Ro (F)

  2008--2012                                  Brazil ([@B189])                   Prospective                   888 (8.1)          29.9 (M), 29.9 (F)   Malar rash, renal disease                                                                                                                                        Anti-dsDNA (M)

                                                                                                                                                                                                                                                                                                                        

  **Scandinavia, Europe, and North Africa**                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                        

  1980--1990                                  Spanish ([@B186])                  Prospective                   261 (11.5)         34 (M), 31 (F)       Discoid lesion, subcutaneous lesion                                               Arthritis, malar rash                                                          6 antibodies assayed, *P* \> 0.05

  1981--2000                                  Greek ([@B184])                    Retrospective                 580 (14)           34.6 (M), 31.4 (F)   NA                                                                                Photosensitivity, RP, oral ulcers, anemia                                      NA

  1982--2012                                  UK (multiethnic) ([@B194])         Retrospective                 484 (9.3)          30.9 (M), 29.1 (F)   NA                                                                                Oral ulcers                                                                    IgM aCL (F)

  1987--2006                                  Spain ([@B191])                    Retrospective                 150 (15.3)         54 (M) 43 (F)        Secondary Sjogren's syndrome (over course of disease), thrombocytopenia           RP                                                                             Anti-SSA/Ro(F)

  1989--2007                                  Greek ([@B179])                    Retrospective                 743 (7.9)          34 (M), 31 (F)       Nephropathy, tendonitis, myositis                                                 NA                                                                             NA

  1990--1999                                  Tunisian ([@B180])                 Retrospective                 295 (8.1)          NA                   Vascular thrombosis                                                               Alopecia                                                                       NA

  1992--2006                                  Spain ([@B182])                    Retrospective                 363 (13)           47.8 (M) 36.6 (F)    Serositis, renal disease, neurologic disorder                                     Leukopenia, alopecia                                                           Anti-DNA (M)

  2000--2008                                  Danish ([@B199])                   Retrospective                 513 (11.5)         46.2 (M), 36.2 (F)   Serositis, nephropathy, hypertension                                              Photosensitivity                                                               3 antibodies assayed, *P* \> 0.05

                                                                                                                                                                                                                                                                                                                        

  **Middle East**                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                        

  1976--2011                                  Iran ([@B188])                     Retrospective                 2355 (10.1)        25 (M), 24.5 (F)     Discoid rash, nephritis                                                           Arthritis, leukopenia                                                          

  1996--2012                                  Turkey ([@B185]) (Mediterranean)   Retrospective                 428 (6.8)          40.4 (M) 38.5 (F)    Renal disease, CNS                                                                Dry eyes, Dry mouth, photosensitivity                                          

                                                                                                                                                                                                                                                                                                                        

  **Asia**                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                        

  1990--1993                                  Asian ([@B192])                    Retrospective                 147 (41.5)         28.2 (M), NA (F)     NA                                                                                Arthritis, leukopenia                                                          Anti-SSA/Ro (F)

  1994--2010                                  Korea ([@B196])                    Retrospective                 632 (9)            32.9 (M) 32.6 (F)    Renal disease                                                                     Discoid rash, alopecia, Leukopenia                                             Anti-SSA/Ro (F)

  1999                                        HongKong (Asian) ([@B32])          Retrospective control         252 (20.2)         31 (M), 31.9 (F)     NA                                                                                RP, alopecia                                                                   Anti-SSA/Ro (F)

  2001                                        Malaysian (Asian) ([@B193])        Prospective                   134 (9.0)          30 (M), 26 (F)       Thrombosis                                                                        Arthritis                                                                      NA

  2006--2010                                  Indian (Asian) ([@B183])                                         250 (11.2)         22.3 (M), 28.3 (F)   Renal disease                                                                     Disease severity                                                               Panel of 13 antibodies, *P* \> 0.05

  2008                                        Thai (Asian) ([@B177])             Retrospective Case--control   111 (33.3)         34.6 (M), 34.4 (F)   ↓ Platelets,\                                                                     Alopecia, arthralgia, RP, psychosis                                            7 antibodies assayed, *P* \> 0.05
                                                                                                                                                       ↑ Serum creatinine                                                                                                                                               

  2010                                        Chinese ([@B181])                  Retrospective                 1790 (9.8)         31.5 (M), 30.9 (F)   Serositis, pleuritis, and discoid rash                                            Malar rash, alopecia, oral ulcers, leukopenia positively correlates with age   Elevated ESR, antinuclear, anti-SSA/Ro and anti-SSB/La (F).\
                                                                                                                                                                                                                                                                                                                        Anti-SSB/La correlates with age (M)
  ------------------------------------------- ---------------------------------- ----------------------------- ------------------ -------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------------------------------

*F, female; M, male; NA, not applicable; DAT, direct antiglobulin test; LAC, lupus anticoagulant; ESR, erythrocyte sedimentation rate; anti-dsDNA, anti-double stranded deoxyribonucleic acid; anti-Sm, anti-Smith; IgG Acl, anti-cardiolipin; anti-Sjögren's syndrome-related antigen A (SSA/Ro), anti- Sjögren's syndrome-related antigen B (SSB/La)*.

###### 

Sex differences in ankylosing spondylitis clinical phenotypes.

  Clinical phenotype                                                     Studies showing phenotype is significantly higher in males   Studies showing phenotype is significantly higher in females   Studies showing statistically insignificant differences in males and females
  ---------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------- ------------------------------------------------------------------------------
  **Baseline characteristics**                                                                                                                                                                       
                                                                                                                                                                                                     
  Age at onset                                                           ([@B200])                                                    ([@B141], [@B201]--[@B204])                                    ([@B19])^R(15)^, ([@B205], [@B206])
  Age at diagnosis                                                                                                                    ([@B141], [@B203], [@B204])                                    ([@B19])^R(15)^, ([@B202], [@B206])
  Delay in diagnosis                                                                                                                  ([@B19])^R(15)^, ([@B205])                                     ([@B141], [@B203], [@B204], [@B206], [@B207])
  Night pain                                                                                                                          ([@B206])                                                      
  Sleep disturbance                                                                                                                   ([@B206])                                                      
  Duration of morning stiffness                                                                                                       ([@B207])                                                      
  Relevant family history                                                                                                             ([@B200], [@B208], [@B209])                                    ([@B202], [@B203])
  HLA-B27--positive, %                                                   ([@B202]--[@B204], [@B209])                                                                                                 ([@B19], [@B141], [@B200], [@B201], [@B205])
                                                                                                                                                                                                     
  **Disease activity and functional index**                                                                                                                                                          
                                                                                                                                                                                                     
  ESR                                                                                                                                 ([@B201], [@B206])                                             ([@B141], [@B202], [@B203], [@B205], [@B207])
  CRP                                                                    ([@B203]--[@B205], [@B208])                                  ([@B201])                                                      ([@B202], [@B206], [@B207])
  Disease activity: BASDAI score                                                                                                      ([@B201], [@B205]--[@B210])                                    ([@B141], [@B202]--[@B204])
  BAS-G                                                                                                                               ([@B208])                                                      ([@B203], [@B205])
  Back pain                                                              ([@B201], [@B202], [@B209])                                  ([@B203], [@B205])                                             
  BASRI                                                                  ([@B207], [@B209], [@B210])                                                                                                 
  BASRI-spinal                                                           ([@B200], [@B201])                                                                                                          
  BASRI-hip                                                              ([@B209])                                                                                                                   
  Physical function: BASFI score                                                                                                      ([@B206], [@B208])                                             ([@B141], [@B200], [@B201], [@B203]--[@B205], [@B207], [@B209], [@B210])
  Spinal mobility: BASMI score                                           ([@B203], [@B204], [@B207])                                  ([@B202])                                                      ([@B205])
  Occiput-to-wall distance                                               ([@B202], [@B207], [@B209], [@B210])                                                                                        
  Chest expansion                                                                                                                                                                                    ([@B202], [@B203], [@B207], [@B209], [@B210])
  Modified Schober's test                                                                                                             ([@B202], [@B209], [@B210])                                    ([@B207])
  Finger-to-floor                                                        ([@B203], [@B209], [@B210])                                                                                                 
  Lumbar rotation                                                                                                                     ([@B203])                                                      
                                                                                                                                                                                                     
  **Clinical data**                                                                                                                                                                                  
                                                                                                                                                                                                     
  MASES                                                                                                                               ([@B204], [@B209])                                             
  Enthesitis                                                                                                                          ([@B202]--[@B208], [@B210])                                    ([@B141], [@B209])
  Swollen joint score                                                                                                                 ([@B204], [@B208], [@B209])                                    ([@B205], [@B210])
  Tender joint score                                                                                                                  ([@B205], [@B207]--[@B209])                                    
  Definite deterioration and radiographic progression---cervical spine                                                                ([@B208], [@B211])                                             ([@B202])
  Cervical pain                                                                                                                                                                                      ([@B203], [@B209])
  Radiographic sacroiliitis, %                                           ([@B208], [@B209])                                                                                                          
  Dactylitis                                                                                                                          ([@B209])                                                      ([@B204], [@B210])
  Root joint involvement (shoulder and hip)                              ([@B205])                                                    ([@B141])                                                      ([@B202], [@B203], [@B209])
  Localization of clinical symptoms to buttock                                                                                        ([@B208])                                                      
  Peripheral arthritis                                                                                                                ([@B204], [@B208])                                             ([@B141])
  Upper limb arthritis (%)                                                                                                            ([@B209])                                                      
  Lower limb arthritis (%)                                                                                                                                                                           ([@B209])
  Knee involvement                                                       ([@B202])                                                                                                                   ([@B203])
  Intensity of axial pain                                                ([@B209])                                                    ([@B208])                                                      
  mSASSS                                                                 ([@B205])                                                                                                                   
  Thoracic syndesmophyte                                                 ([@B202])                                                    ([@B203])                                                      
  Bamboo spine                                                           ([@B202])                                                                                                                   
  Definite deterioration and radiographic progression---lumbar spine     ([@B211])                                                                                                                   ([@B202])
  MRI-inflammatory lesions of the spine, %                               ([@B208])                                                                                                                   ([@B210])
  Uveitis                                                                                                                             ([@B141], [@B202])                                             ([@B203]--[@B205], [@B209])
                                                                                                                                                                                                     
  **Measures of Quality of Life**                                                                                                                                                                    
                                                                                                                                                                                                     
  SF-36 mental score                                                     ([@B205], [@B208])                                                                                                          
  SF-36 physical score                                                   ([@B208])                                                                                                                   ([@B205])
  ASQoL score                                                                                                                         ([@B209], [@B210])                                             ([@B203], [@B205])
  EuroQoL score                                                                                                                                                                                      ([@B205])
  HAQ-AS                                                                                                                              ([@B208])                                                      ([@B200])

*The results depict studies where significant (*P* \< 0.05) differences were detected; ^R(x)^ indicates meta-analysis of x number of published studies; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BAS-G, Bath Ankylosing Spondylitis Patient Global disease activity score; BASRI, The Bath Ankylosing Spondylitis Radiology Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; mSASSS, modified Stoke Ankylosing Spondylitis (AS) Spine Score; SF-36, Medical Outcomes Study 36-item Short Form; ASQoL, Ankylosing Spondylitis Quality of Life Questionnaire; EuroQoL, European Quality Of Life scale; HAQ-AS, Health Assessment Questionnaire for the Spondyloarthropathies*.

###### 

Comparative studies of male and female ankylosing spondylitis: main clinical and demographic findings.

  Year of Study                      Country (ethnicity)                                                                                  Study type        Size (% female)   Age at onset         Clinical data (*P* \< 0.05)                                                                                                                                                     Serology                                                                                                                                                                                   
  ---------------------------------- ---------------------------------------------------------------------------------------------------- ----------------- ----------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------
  **North America**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2007                               USA (White, African American, Asian/Pacific Islander, Native American, Hispanic, others) ([@B200])   Prospective       402 (24.9)        23.6 (M), 21.5 (F)   BASRI, BASFI and HAQ-S (when adjusted for BASRI), thoracic, and lumbar spinal radiographic severity                                                                             AS family history, neck and peripheral joint pain^\#^                                                                                                                                      NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Latin America**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2006--2009                         Brazil ([@B209])                                                                                     Prospective       1,505 (27.6)      NA                   \% of HLA-B27+ patients, axial inflammatory pain, lumbar pain, urethritis, occiput-to-wall and finger-to-floor distances, BASRI, BASRI-spine, BASRI-hip, grade 4 sacroiliitis   AS family history, upper limb arthritis, dactylitis and nail involvement, psoriasis, number of painful and swollen joints, MASES, BASDAI, ASQoL, Schober's test                            NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2006                               Argentina, Brazil, Costa Rica, Chile, Ecuador, Mexico, Peru, Uruguay, and Portugal ([@B210])         Cross-sectional   1,072 (23.8)      NA                   BASRI, occiput-to-wall and finger-to-floor distance                                                                                                                             BASDAI, ASQoL, Enthesitis, Schober's test                                                                                                                                                  NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Europe**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2004--2009                         UK ([@B206])                                                                                         Prospective       516 (66.7)        NA                                                                                                                                                                                                   Night pain, sleep disturbance, BASDAI score, BASFI score                                                                                                                                   ESR (F)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2005--2016                         Switzerland ([@B204])                                                                                Prospective       440 (33.2)        25 (M), 27.3 (F)     \% of HLA-B27+ patients, BASMI score                                                                                                                                            Diagnostic delay, peripheral arthritis, number of swollen joints, % enthesitis, MASES                                                                                                      CRP (M)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2004--2013                         Spain ([@B201])                                                                                      Retrospective     1,514 (25.3)      26.7 (M), 28.2 (F)   Lumbalgia                                                                                                                                                                       AS family history                                                                                                                                                                          NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2007--2010                         France ([@B208])                                                                                     Prospective       475 (49.7)        NA                   SF-36 mental and physical scores, % radiographic sacroiliitis, MRI-inflammatory lesion of sacroiliac joints and spine                                                           Pain at cervical spine, buttock, axial, and peripheral joint pain intensity, tender joint and swollen joint scores, MASES, AS family history, BASDAI, BAS-G, BASFI scores, HAQ-AS, ASQoL   CRP (M)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1996--2008                         Netherlands, Belgium, France ([@B205])                                                               Prospective       216 (62)          23.1 (M), 23.3 (F)   Hip involvement, SF-36 mental score, mSASSS                                                                                                                                     BASDAI, back pain, tender joint count, MASES                                                                                                                                               CRP (M)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Middle East and North Africa**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2010--2011                         Iran (Fars, Turk, Kurd, Lor, and others) ([@B203])                                                   Prospective       320 (20.9)        22.2 (M), 24.3 (F)   \% of HLA-B27+ patients, tragus-to-wall and finger-to-floor distances, BASMI, lateral lumbar flexion score                                                                      Enthesitis (thoracic, chest wall), elbow joint involvement, back pain, degree of lumbar rotation, lateral lumbar flexion distance, modified Schober's test                                 CRP (M)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2009--2010                         Morocco ([@B207])                                                                                    Prospective       130 (33.1)        27.9 (M), 28.8 (F)   Occiput-wall distance, BASMI, BASRI                                                                                                                                             Duration of morning stiffness, number of tender joints, BASDAI, Schober's test, MEI                                                                                                        NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Asia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2009                               India ([@B141])                                                                                      Prospective       70 (15.7)         22.3 (M), 30.0 (F)   NA                                                                                                                                                                              Uveitis, root joint involvement                                                                                                                                                            NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2006                               Korea ([@B202])                                                                                      Cross-sectional   505 (14.1)        25.0 (M), 27.7 (F)   \% of HLA-B27+ patients, joint pain, higher occiput-to-wall distance, thoracic syndesmophyte, bamboo spine                                                                      Uveitis, modified Schober's test, knee joint involvement, plantar fasciitis                                                                                                                NA

*F, female; M, male; NA, not applicable; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BAS-G, Bath Ankylosing Spondylitis Patient Global disease activity score; BASRI, The Bath Ankylosing Spondylitis Radiology Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; mSASSS = modified Stoke Ankylosing Spondylitis (AS) Spine Score; SF-36 = Medical Outcomes Study 36-item Short Form; ASQoL = Ankylosing Spondylitis Quality of Life Questionnaire; HAQ-AS = Health Assessment Questionnaire for the Spondyloarthropathies; MEI = Mander enthesis index*.

Results {#S3}
=======

Males and Females Have Different Biological Landscapes {#S3-1}
------------------------------------------------------

A report released by the Institute of Medicine in 2001, "Exploring the Biological Contributions to Human Health: Does Sex Matter?" describes in great detail the different factors that contribute to biological differences in males and females, and how these differences affect health and diseases in these two sexes ([@B11]). Beyond the overt differences in reproductive biology, males and females show differences in immune functions, brain organization, pain perception, gene dosing (for genes that escape X-chromosome inactivation) as well as metabolism, lifestyle, and physical performance, all of which may alter pharmacokinetic and pharmaco-dynamic variables in the two sexes ([@B11]). Males and females operate from different biological landscapes, be it in healthy, diseased, or recovering states.

To explain autoimmune sex dimorphism, it becomes necessary to first describe the cellular and hormonal interactions found in normal immune regulation and thereafter extrapolate these to autoimmune phenomena. In comparison to the innate immunity, the adaptive immune system is known to be significantly affected by sex. Adult females in general, show stronger immune responses than others, and these responses are partially modulated by sex hormones ([@B3], [@B4], [@B6], [@B11]). Other contributing parameters include genetic and environmental factors; we refer the readers to a string of excellent reviews for in-depth discussions of these factors ([@B3]--[@B10]). We summarize the sex dichotomy in normal immune system biology in Table [1](#T1){ref-type="table"} ([@B3]). All components of the innate immunity, such as the toll-like receptor pathway, antigen-presenting cells, dendritic cells, macrophages, granulocytes, and natural killer cells, show stronger activity in females. Despite the lower CD8+ T-cell count, the cytotoxicity of each of these cells is higher in females. As estrogen and progesterone levels wax and wane during the menstrual cycle, the balance between T~H~1 and T~H~2 system fluctuates. This balance and its interactions with other systems such as the T~H~17, T~reg~, and B-cells dictate the overall immune response. Disruptions to the equilibrium of these different systems lead to different AD pathologies and disease onsets in males and females ([@B6]).

ADs Show Stronger Female Bias {#S3-2}
-----------------------------

There are currently more than one hundred identified ADs, with 24 showing high prevalence (occurring in 1 per 10,000 people) ([@B212]). 71% of these common ADs (Figure [1](#F1){ref-type="fig"} below, in bold) are more prevalent in females than males (\>50% female prevalence), suggestive of a stronger female bias ([@B213]). However, these data were an aggregated one from "world," and "USA" ([@B213]). In Table [2](#T2){ref-type="table"}, we stratify some of these ADs by geographical location (as a proxy for ethnicity), in order to gain a better insight of each AD's prevalence in different parts of the world. In addition, we include three ADs which have been reported to be more prevalent in males: idiopathic pulmonary fibrosis (IPF), ankylosing spondylitis (AS), and Guillain--Barré syndrome (GBS). Table [2](#T2){ref-type="table"} shows that female predominance prevails in all three systemic ADs. Regardless of the geography, females are more than thrice as likely as males to suffer from systemic ADs. For instance, Spanish women are 18.6 times more likely than men to suffer from Sjögren's syndrome (SS). A similar trend is also observed with endocrine ADs: Grave's disease and Hashimoto's thyroiditis (HT). In India, the female to male ratio for HT is an astonishing 21.7 to 1. Another strong female bias (at least a 2:1 female to male ratio worldwide) is observed with some gastrointestinal and hepatic ADs (primary biliary cholangitis and autoimmune hepatitis), as well as a musculoskeletal AD (rheumatoid arthritis).

![List of Autoimmune Diseases (ADs) with prevalence ≥ 1 per 10,000 people.](fimmu-09-01208-g001){#F1}

Although a strong female preponderance was observed with other ADs, these tend to vary with geographical locations. For example, antiphospholipid syndrome shows a female to male ratio of at least 3:1 worldwide, except in Spain and Italy, where it shows lower ratios (2.1:1 and 1.7:1, respectively). Immune thrombocytopenic purpura (ITP) was reported to have a 70% female prevalence in Denmark ([@B213]); however, the sex ratio is much lower in our dataset, ranging from 1.1:1 in the USA to 1.7:1 in France. Asian females seem to be more likely to get ITP than other ethnicities, with a female to male ratios ranging from 1.9:1 in India to 4.3:1 in Singapore. Other ADs reported include celiac disease (CoD) and ulcerative colitis (UC), which affected 57 and 65% of females, respectively ([@B213]). The female-to-male ratios for CoD and UC vary in our dataset, favoring males or females depending on geography. In Italy, UK, and India, males are more likely to suffer from CoD than females, whereas the reverse is true in Denmark and Sweden. In Asia, males are more likely to suffer from UC than in the Western world. AS and GBS show greater bias toward males, regardless of the geographical locations. In IPF, however, male predominance was observed all around the world except for the North Americas.

ADs Have Different Trajectories in Different Sexes {#S3-3}
--------------------------------------------------

Autoimmune diseases are quintessentially immune system disorders. As the biology of the immune system varies between the two sexes, one would expect ADs to have different disease trajectories in males and females. Here, we utilize a female-biased AD: systemic lupus erythematosus (SLE), as well as a male-biased AD: ankylosing spondylitis (AS) to exemplify sex-bias in disease progression, complications, and mortality. SLE and AS data are stratified by clinical data, geography, and period of study, since older studies may suffer from delayed diagnoses in male SLE and female AS patients (Tables [3](#T3){ref-type="table"}--[6](#T6){ref-type="table"}).

In SLE, clinical phenotypes show sex-bias. Alopecia, photosensitivity, malar rash, Raynaud's phenomenon, musculoskeletal complications, oral ulcers as well as psychiatric disorders are female-biased (Table [3](#T3){ref-type="table"}). In addition, females are more likely to suffer from relapses and a concurrent diagnosis for SS. Male-specific clinical phenotypes include discoid lesions, serositis, renal disease, seizure, and peripheral neuropathy, as well as cardiovascular complications. Males also tend to display constitutional symptoms and higher score in Systemic Lupus Erythematosus Disease Activity Index, indicative of a higher disease activity. Indeed, higher mortality has been reported in male patients vs female patients. Serology in SLE also shows some sex-bias: females SLE patients more frequently present with higher erythrocyte sedimentation rate (ESR) and test positive for anti-SSA/Ro while the male SLE patients more frequently test positive for lupus anticoagulant, anti-Sm, anti-dsDNA, and hypocomplementemia.

In AS, clinical phenotypes also show some degree of sex-bias. Male AS patients tend to have disease onset at younger age and present with higher CRP, more back pain, knee involvement, higher scores for BASRI (including BASRI-spinal and BASRI-hip), radiographic sacroilitis, higher modified Stoke Ankylosing Spondylitis Spinal Score, lower functional indices (occiput-to-wall and finger-to-floor distances), but higher SF-36 mental and physical scores. Female AS patients, on the other hand, present more with AS family history, higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score, enthesitis, more numbers of swollen, tender joints and peripheral arthritis but higher ASQoL score. Notably, in a multivariate model, Lee et al. found that for a given level of radiographic damage, female AS patients have more functional limitations than their male counterparts ([@B200]).

Discussion {#S4}
==========

In this systematic review, we summarize sex differences in immune system biology, AD prevalence, as well as clinical phenotypes of SLE and AS. Data accrued highlight female predominance in common ADs, although there exist geographical differences in some cases. These observed geographical differences are suggestive of potential contributions of genetics and environmental factors toward AD pathology.

In SLE, disease complications and serology seem to show sex-bias. Alopecia, for example, is exclusively observed in females just as serositis is exclusively seen in males. It is interesting how the serology in these males and females is reflective of sex-bias in clinical phenotypes. In The Genetic Profile Predicting the Phenotype (PROFILE) multiethnic cohort of 2,322 SLE patients, anti-Sm were significantly associated with antinuclear antibody, anti-double-stranded DNA (dsDNA), and clinical phenotypes, such as serositis, renal involvement, psychosis, vasculitis, Raynaud's phenomenon, hemolytic anemia, leukopenia, lymphopenia, and arterial hypertension ([@B214]). Furthermore, double positive serology for anti-Sm and anti-dsDNA has been strongly associated with renal involvement ([@B215]--[@B218]) and higher disease activity ([@B219]). Most of these clinical phenotypes are male-specific SLE complications (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Similarly, anti-SSA/Ro antibodies have been reported to be strongly associated with low C3 (hypocomplementemia) and clinical phenotypes such as photosensitivity, subacute cutaneous lupus erythematosus, cutaneous vasculitis (palpable purpura), hematological disorder (anemia, leukopenia, and thrombocytopenia) ([@B220]--[@B227]), as well as Jaccoud's arthropathy (a type of arthritis) ([@B228], [@B229]). These phenotypes show female bias in our dataset (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). There are some clinical phenotypes such as mucocutaneous and hematological involvements, vasculitis, and association of anti-SSA/Ro with low C3 that differ between these correlation studies and our dataset. This may arise either from ethnic or age differences in the different study groups, or the size of the study groups. The trend for renal involvement persists in all of the studies we have analyzed; however, this clinical phenotype may or may not show a statistical difference for sex-bias owing to the low number of male SLE patients in some studies.

We also observed sex-bias in our dataset for AS clinical phenotypes: female AS patients present with enthesitis and higher BASDAI scores, while male patients present with higher BASRI scores. AS is clinically tested with HLA-B27, ESR, and CRP. While some studies suggested that high CRP is more significantly seen in male patients and high ESR with female patients, many other studies have not come to similar conclusions.

The findings from SLE and AS suggest that disease phenotypes differ between males and females. In some cases, these diseases arguably have higher activity in the sex having lower prevalence. Awareness of sex-bias in disease presentation is crucial for early diagnosis, as well as treatment strategies for ADs in different sexes. More importantly, such awareness may guide the development of improved study design strategies for biomarker discovery.

Future Direction and Conclusion {#S5}
===============================

Timely diagnosis and treatment can be very effective for AD patients ([@B230], [@B231]) and biomarkers have great potential to enable it. Although AD biomarkers discovery is thriving, the same cannot be said of their clinical translation. Many biomarker projects fail at validation/replication stage ([@B13]) due to suboptimal sensitivity and specificity, as well as reproducibility in different studies ([@B12]). A few potential contributing factors to this observed failure include suboptimal infrastructure, study design, and execution in discovery-phase ([@B12]). Suboptimal study design includes small sample numbers, lack of patient history and subject matching (in terms of age, race, and sex) ([@B12]). Here we highlight the importance of sex stratification in biomarker discovery studies to promote reproducibility in replication/validation stage. Drawing example from SLE and AS, we note that differential clinical phenotypes exist in male and female patients. Different sexes may require different biomarkers for proper diagnosis of the same disease. From SLE serology we learn that some biomarkers are more frequently detected in one specific sex, and they show strong associations with sex-biased clinical phenotypes. Such specific associations may be missed when data from both sexes are aggregated.

In addition to enhancing sex-specific biomarker discovery and promoting reproducibility, a thorough understanding of sex differences in autoimmune milieu may guide disease prevention, diagnosis, and management. Our findings in Table [2](#T2){ref-type="table"} clearly demonstrate a higher prevalence ADs among females. Breast cancer screening mammography among women at average risk aged 50--74 has been shown to reduce breast cancer mortality by 30--40% ([@B232]). These findings suggest potential benefits of AD screenings specifically for women, for early AD detection and reduction of mortality rates through early intervention. Another plausible area of further study is to sex-stratify serological benchmarks for males and females, in light of varying cytokine levels and activity in different sexes as observed in Table [1](#T1){ref-type="table"}. We have limited our scope in this review to SLE, AS and sex stratification. Further stratifications for improved patient segmentation and more specific biomarker discovery may include stratifications by age, ethnicities and disease stages.
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